Research Article
Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases
Table 1
Patients’ characteristics.
| | | AILD () | AIH () | Overlap syndrome () | |
| | Age, years (M ± SD) | 48.2 ± 15.1 | 43.2 ± 15.5 | 53.9 ± 12.6 | | | Gender, females (%) | 54 (90%) | 28 (87.5%) | 26 (92.8%) | | | Symptom duration, years (M ± SD) | 5.9 ± 5.6 | 6.9 ± 6.3 | 4.7 ± 4.5 | | | Jaundice (%) | 36 (60%) | 17 (53.1%) | 19 (67.9%) | | | Abdominal discomfort (%) | 34 (56.7%) | 16 (50%) | 18 (64.3%) | | | Extrahepatic signs (%) | 41 (68.3%) | 23 (71.9%) | 17 (60.7%) | | | Cirrhosis (%) | 43 (71.7%) | 23 (71.9%) | 20 (71.4%) | | | Hemoglobin, g/L (M ± SD) | 120.9 ± 15.1 | 118.1 ± 20.2 | 124.2 ± 18.3 | | | ESR, mm/h (M ± SD) | 24.7 ± 14.9 | 17.3 ± 12.1 | 33.12 ± 13.3 | | | ALT, U/L (M ± SD) | 107.6 ± 143.1 | 68.8 ± 72.8 | 147.8 ± 183.6 | | | AST, U/L (M ± SD) | 84.4 ± 68.0 | 72.9 ± 68.4 | 96.7 ± 66.6 | | | Alkaline phosphatase, U/L (M ± SD) | 220.4 ± 68.0 | 107.7 ± 71.4 | 337.8 ± 176.9 | | | GGT, U/L (M ± SD) | 258.9 ± 296.1 | 134.3 ± 135.8 | 389.1 ± 359.9 | | | Total bilirubin, μmol/L (M ± SD) | 58.9 ± 100.5 | 59.6 ± 91.47 | 58.2 ± 111.0 | | | Total IgG, mg/mL (M ± SD) | 18.2 ± 5.3 | 18.6 ± 5.6 | 17.8 ± 4.8 | | | Circulating immune complexes, U/L (M ± SD) | 241.1 ± 165.3 | 205.2 ± 133.6 | 283.5 ± 190.8 | | | Albumin, g/L (M ± SD) | 48.3 ± 5.3 | 47.9 ± 5.9 | 48.9 ± 4.3 | | | Gamma-globulin, g/L (M ± SD) | 24.9 ± 5.7 | 26.1 ± 6.2 | 23.2 ± 4.5 | | | UDCA intake (%) | 52 (86.7%) | 25 (78.1%) | 27 (96.4%) | | | GC intake (%) | 20 (33.3%) | 25 (78.1%) | 15 (53.6%) | | | GC dose, mg/day (M ± SD) | 17.0 ± 11.8 | 26.1 ± 6.2 | 17.8 ± 15.5 | | | AZA intake (%) | 6 (10%) | 5 (15.6%) | 1 (3.6%) | |
|
|
AILD: autoimmune liver disease; AIH: autoimmune hepatitis; ESR: erythrocyte sedimentation rate; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; UDCA: ursodeoxycholic acid; GC: glucocorticoids; AZA: azathioprine.
|
